---
schema_version: "secwatch.filing_event.v1"
accession: "0001528287-25-000006"
form_type: "8-K"
ticker: "NPCE"
cik: "0001528287"
company_name: "NeuroPace Inc"
filed_at: "2025-03-04T23:59:59+00:00"
generated_at: "2026-05-25T13:52:53.160310+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# NeuroPace reports Q4 revenue $21.5M (+19% YoY); guides FY2025 revenue $92-96M

## Summary
- Q4 2024 revenue $21.5M (+19% YoY); full year revenue $79.9M (+22%).
- Net loss improved: Q4 $5.3M (vs $6.2M); full year $27.1M (vs $33.0M).
- FY2025 guidance: revenue $92-96M (15-20% growth), gross margin 73-75%, operating expenses $92-95M.
- Completed $74.8M public offering; used $49.5M to repurchase 5.3M shares from KCK Ltd.; pro forma cash $68.6M.
- NAUTILUS study completes March 2025; FDA submission H2 2025; NEST pediatric program for indication expansion.

## SEC filing metadata
- accession: 0001528287-25-000006
- form_type: 8-K
- ticker: NPCE
- cik: 0001528287
- company_name: NeuroPace Inc
- filed_at: 2025-03-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1528287/000152828725000006/0001528287-25-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1528287/000152828725000006/npce-20250304.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001528287-25-000006
- JSON: https://secwatch.observer/filing/0001528287-25-000006.json
- Plain text: https://secwatch.observer/filing/0001528287-25-000006.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.